Eli Lilly and Company (NYSE:LLY) Stock Position Decreased by Consilium Wealth Advisory LLC

Consilium Wealth Advisory LLC lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 12.0% during the third quarter, HoldingsChannel.com reports. The fund owned 3,982 shares of the company’s stock after selling 545 shares during the period. Eli Lilly and Company accounts for about 1.9% of Consilium Wealth Advisory LLC’s portfolio, making the stock its 15th biggest position. Consilium Wealth Advisory LLC’s holdings in Eli Lilly and Company were worth $3,528,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. M&G Plc bought a new stake in shares of Eli Lilly and Company during the first quarter valued at approximately $8,896,000. Virtu Financial LLC acquired a new position in Eli Lilly and Company during the 1st quarter worth $2,138,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Eli Lilly and Company by 19.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after purchasing an additional 1,620 shares during the period. Chesley Taft & Associates LLC raised its stake in shares of Eli Lilly and Company by 5.4% during the second quarter. Chesley Taft & Associates LLC now owns 22,553 shares of the company’s stock valued at $20,419,000 after purchasing an additional 1,163 shares in the last quarter. Finally, OMNI 360 Wealth Inc. acquired a new stake in Eli Lilly and Company in the second quarter worth about $239,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 3.9 %

Shares of NYSE LLY traded down $31.07 during mid-day trading on Wednesday, reaching $774.99. The company had a trading volume of 2,021,283 shares, compared to its average volume of 3,058,355. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The company has a market capitalization of $735.71 billion, a price-to-earnings ratio of 87.20, a PEG ratio of 3.09 and a beta of 0.43. The stock has a fifty day moving average of $905.20 and a two-hundred day moving average of $867.96. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. During the same quarter in the previous year, the company earned $0.10 EPS. The firm’s quarterly revenue was up 20.4% compared to the same quarter last year. As a group, equities research analysts expect that Eli Lilly and Company will post 13.23 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a $1.30 dividend. The ex-dividend date is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.67%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 56.22%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Truist Financial boosted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Barclays cut their target price on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Sanford C. Bernstein began coverage on Eli Lilly and Company in a report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price objective for the company. Finally, JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Four investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,008.41.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.